Regeneron reported Q4 2024 earnings today and declared its first-ever dividend of $0.88 per quarter. Click here to know what ...

Beyond CSCC, Libtayo is authorised to treat basal cell carcinoma, the most common type of skin cancer, as well as non-small cell lung cancer (NSCLC). Regeneron recently presented five-years results ...

Libtayo has been approved by regulatory authorities in more than 30 countries in one or more indications, including for certain adult patients with advanced basal cell carcinoma (BCC), advanced CSCC, ...

Cemiplimab (Libtayo, Regeneron Pharmaceuticals ... It also is approved for treatment of certain patients with basal cell carcinoma or non-small cell lung cancer. Adjuvant cemiplimab prolonged ...

Sanofi and Regeneron's checkpoint inhibitor Libtayo has tripled its approved uses in Europe, after getting the nod for the treatment of advanced basal cell carcinoma (BCC) and advanced non-small ...

It is looking to strengthen its oncology franchise, which currently comprises Libtayo (cemiplimab-rwlc), indicated in certain patients with advanced basal cell carcinoma, advanced cutaneous ...

Fianlimab (LAG3) for melanoma: Combining fianlimab and Libtayo, two potentially best ... People with a type of skin cancer called basal cell carcinoma (BCC) when your BCC cannot be removed by ...

Fianlimab (LAG3) for melanoma: Combining fianlimab and Libtayo, two potentially best-in-class checkpoint ... People with a type of skin cancer called basal cell carcinoma (BCC) when your BCC cannot be ...

The EC approval also now means that Libtayo can be used to treat certain patients across four types of cancer within the European Union: advanced squamous cell carcinoma (SCC), advanced basal cell ...

REGN is looking to strengthen its oncology franchise, which currently comprises Libtayo (cemiplimab-rwlc), indicated in certain patients with advanced basal cell carcinoma, advanced cutaneous ...